IR@PKUHSC  > 北京大学临床肿瘤学院  > 胸部肿瘤内科
学科主题临床医学
Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
Wang, Fen; Wang, Shuhang; Wang, Zhijie; Duan, Jianchun; An, Tongtong; Zhao, Jun; Bai, Hua; Wang, Jie
关键词EGFR phosphorylation EGFR mutation Non-small cell lung cancer
刊名JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
2012-08-18
DOI10.1186/1756-9966-31-65
31
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]GROWTH-FACTOR RECEPTOR ; CELL LUNG-CANCER ; TYROSINE KINASE DOMAIN ; PULMONARY ADENOCARCINOMA ; MOLECULAR PREDICTORS ; ACTIVATING MUTATIONS ; POOR-PROGNOSIS ; ERBB RECEPTORS ; TUMOR RESPONSE ; GEFITINIB
英文摘要

Background: EGFR mutation is a strong predictive factor of EGFR-TKIs therapy. However, at least 10% of patients with EGFR wild-type are responsive to TKIs, suggesting that other determinants of outcome besides EGFR mutation might exist. We hypothesized that activation of phosphorylated EGFR could be a potential predictive biomarker to EGFR-TKIs treatment among patients in wild-type EGFR.

Method: Total of 205 stage IIIb and IV NSCLC patients, tissue samples of whom were available for molecular analysis, were enrolled in this study. The phosphorylation of EGFR at tyrosine 1068 (pTyr1068) and 1173 (pTyr1173) were assessed by immunohistochemistry, and EGFR mutations were detected by denaturing high performance liquid chromatograph (DHPLC).

Results: Among 205 patients assessable for EGFR mutation and phosphorylation analysis, 92 (44.9%) were EGFR mutant and 165 patients (57.6%) had pTyr1173 expression. Superior progression-free survival (PFS) was seen after EGFR-TKIs therapy in patients with pTyr1068 expression compared to pTyr1068 negative ones (median PFS 7.0 months vs. 1.2 months, P < 0.001). Inversely, patients with pTyr1173 had a shorter PFS (4.8 months VS. 7.7 months, P = 0.016). In subgroup of patients with wild-type EGFR, pTyr1068 expression positive ones had a significantly prolonged PFS (4.2 months vs. 1.2 months P < 0.001) compared with those without pTyr1068 expression. Sixteen patients with both wild-type EGFR and pTyr1068 who responded to EGFR-TKIs had median PFS of 15.6 months (95% CI: 7.28-23.9).

Conclusion: pTyr1068 may be a predictive biomarker for screening the population for clinical response to EGFR-TKIs treatment; especially for patients with wild-type EGFR.

语种英语
WOS记录号WOS:000313890400001
项目编号30772472
资助机构China National Funds for Distinguished Young Scientists ; Capital Development Foundation
引用统计
被引频次:16[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/64480
专题北京大学临床肿瘤学院_胸部肿瘤内科
作者单位Peking Univ, Dept Thorac Med Oncol, Sch Oncol, Beijing Canc Hosp & Inst, Beijing 100036, Peoples R China
推荐引用方式
GB/T 7714
Wang, Fen,Wang, Shuhang,Wang, Zhijie,et al. Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR[J]. JOURNAL OF EXPERIMENTAL &amp; CLINICAL CANCER RESEARCH,2012,31.
APA Wang, Fen.,Wang, Shuhang.,Wang, Zhijie.,Duan, Jianchun.,An, Tongtong.,...&Wang, Jie.(2012).Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR.JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH,31.
MLA Wang, Fen,et al."Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR".JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 31(2012).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wang, Fen]的文章
[Wang, Shuhang]的文章
[Wang, Zhijie]的文章
百度学术
百度学术中相似的文章
[Wang, Fen]的文章
[Wang, Shuhang]的文章
[Wang, Zhijie]的文章
必应学术
必应学术中相似的文章
[Wang, Fen]的文章
[Wang, Shuhang]的文章
[Wang, Zhijie]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。